Koen Pharmaceuticals: Approval of Clinical Trial Application for SKB103, a New Drug by the Controlling Subsidiary

MetaMuskRat · 2026-03-25T22:28:52+00:00

People Finance News on March 24: Collen Pharma (002422) announced on March 24 that SKB103, a bispecific antibody-drug conjugate (bsADC) targeting tumor-associated antigens (TAA) and immunooncology antigen programmed death-ligand 1 (PD-L1), independently developed by its controlling subsidiary Collen Biotechnology, has received approval from the National Medical Products Administration's Center for Drug Evaluation for a new drug investigational new drug (IND) application for the treatment of advanced solid tumors.

MetaMuskRat

2026-03-25 22:28:52

People’s Financial News, March 24 — Kelun Pharmaceutical (002422) announced on March 24 that its wholly owned subsidiary Kelun Botai’s new drug clinical trial (IND) application for the bispecific antibody-drug conjugate (bsADC) SKB103, targeting novel tumor-associated antigens and immune-oncology antigens (TAA - Programmed Death Ligand 1 (PD-L1)), has been approved by the National Medical Products Administration’s Drug Evaluation Center for the treatment of advanced solid tumors.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.